Key Drivers
- Strong cash conversion
- Modest liquidity decline
- High intangible exposure
AIAI Summary
STERIS's selloff may offer an entry point, but the investment thesis now hinges on proving that recurring consumables growth can sustain margin expansion and attractive returns on its $600 million chemistry buildout despite tariffs and tighter liquidity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash conversion
- •Modest liquidity decline
- •High intangible exposure
STE delivers strong profitability and cash flow, but weakening liquidity, high intangibles, and rising valuation multiples warrant a cautious hold.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Persistent selling
- •Oversold momentum
STE is in a strong bearish trend over the last month, with $205 support critical; an oversold RSI may spark a rebound, but a break below $205 would reinforce downside risk.
RSI near 10 signals unusually intense selling
Sentiment & News
Key News Insights:
- •Recurring demand
- •Margin improvement
- •Chemistry expansion
STERIS' recurring healthcare demand and margin gains support growth, but tariffs and its $600M chemistry expansion raise spending and execution risks.
The news is moderately positive for STERIS, though valuation upside may be constrained by investment and tariff pressures
Similar Companies in Healthcare
Other companies in the same sector with AI ratings